Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 9Esophageal Squamous Cell Carcinoma 5Neoplasm Metastasis 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Recurrence 3Colorectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Sarcoma 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Locally Advanced or Metastatic Urothelial Bladder Cancer 1

Interventions

Radiotherapy 11Cisplatin 10Paclitaxel 9pembrolizumab 7Fluorouracil 7Oxaliplatin 6Irinotecan 6tislelizumab 5Cetuximab 5Docetaxel 4Radiation 3Nivolumab 3Leucovorin 3Carboplatin 3Capecitabine 3Neoadjuvant Therapy 2Immunohistochemistry 2Biopsy 210-propargyl-10-deazaaminopterin 2tremelimumab 1sitravatinib 1sintilimab 1regorafenib 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1oblimersen 1durvalumab 1cixutumumab 1adavosertib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Esophageal Squamous Cell Carcinoma × tislelizumab × Clear all
NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

BeOne Medicines

Phase 3 Completed
370 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeiGene

Phase 3 Completed
649 enrolled 22 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

BeiGene

Phase 2 Terminated
96 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04732494 2025-01-31

AdvanTIG-203

BeiGene

Phase 2 Completed
125 enrolled 25 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeiGene

Phase 3 Completed
512 enrolled 27 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡